About SIMCERE PHARMA Company

Xiansheng Pharmaceutical Group Co., Ltd. (the “Company”, together with its subsidiaries, the “Group”) is an innovative and research-driven pharmaceutical company with R&D, production and specialized marketing capabilities. The Group focuses on the fields of oncology, nervous system, autoimmunity and anti-infection, and actively forwardly lays out disease fields with major clinical needs in the future, and is committed to achieving the corporate mission of “enabling patients to use more effective drugs as soon as possible”. Within the focus area, the Group has six innovative drugs approved for marketing. As of December 31, 2023, 14 products of the Group have entered the guidelines and routes issued by more than 100 government agencies or authoritative professional societies, and more than 40 products have been included in the National Medical Insurance Drug List (“NRDL”). The Group attaches great importance to building innovative drug research and development capabilities, and has established innovation centers in Shanghai, Nanjing, Beijing, Boston and Hong Kong, as well as national key laboratories for neurological and oncology drug research and development. The Group's R&D system covers the entire process from drug discovery, pre-clinical development, clinical testing, and registration, and has leading platforms such as protein engineering, multi-antitic/TCE, multi-antibody/NKCE, AI-assisted molecular generation, protein degradation, and ADC. As of December 31, 2023, the Group had about 1,000 R&D personnel (including about 170 doctorates and 490 master's degrees). The Group has a nationwide marketing network and leading commercialization capabilities, and will continue to strengthen marketing specialization capabilities and improve drug coverage and accessibility. As of December 31, 2023, the Group's four major marketing divisions, neuroscience, anti-cancer, self-prevention and comprehensive, retail, and other marketing support departments, had a total of about 4,200 personnel, spread across 32 provinces, cities and autonomous regions in China. The products covered more than 2,800 tertiary hospitals, about 17,000 other hospitals and medical institutions, and more than 200 large national or regional pharmacy chains across the country. The Group has built production facilities and quality management systems that meet international standards to continuously improve pharmaceutical production capacity. The five pharmaceutical production bases that have been put into use all meet China's GMP requirements, and some production lines have passed EU GMP certification or US Food and Drug Administration (“FDA”) inspection. Driven by independent research and collaborative innovation, the Group has established strategic partnerships with many innovative enterprises, research institutes and clinical centers at home and abroad to explore various collaborative models for cooperative research and development, transfer of results, etc., and continuously explore products that patients need and have huge market potential. The Group has established a Scientific Advisory Board (SAB), bringing together more than a dozen world-leading scientists in the fields of oncology, nervous system, autoimmunity, etc., to use their professional abilities and industry experience to provide scientific advice for the Group's early drug discovery and clinical development, and explore and create unprecedented treatments.